Indication

AROMASIN is indicated for:

  • the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to AROMASIN for completion of a total of 5 consecutive years of adjuvant hormonal therapy.
  • the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Important Safety Information

AROMASIN is contraindicated in patients with known hypersensitivity to the drug or to any of the excipients and in women who are premenopausal, pregnant, or who may become pregnant; the patient should be apprised of the potential hazard to the fetus.

AROMASIN should not be co-administered with estrogen-containing agents as these could interfere with its pharmacologic action.

Reductions in bone mineral density (BMD) over time are seen with AROMASIN use. Clinical fractures were reported in 4.2% of patients receiving AROMASIN and in 3.1% of patients receiving tamoxifen. Therefore, women with osteoporosis or at risk of osteoporosis should have their BMD formally assessed at the commencement of adjuvant treatment with exemestane. Patients treated with exemestane should be carefully monitored and treatment for osteoporosis should be initiated as appropriate.

Adverse Events (AEs): AROMASIN was generally well tolerated and adverse events were usually mild to moderate.

  • Early breast cancer: AEs occurring in ≥10% of patients in any treatment group (AROMASIN vs tamoxifen) were hot flushes (21.2% vs 19.9%), fatigue (16.1% vs 14.7%), arthralgia (14.6% vs 8.6%), headache (13.1% vs 10.8%), insomnia (12.4% vs 8.9%), and increased sweating (11.8% vs 10.4%). Discontinuation rates due to AEs were similar between AROMASIN and tamoxifen. The incidence of cardiac ischemic events (myocardial infarction, angina, and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%. The incidence of cardiac failure was AROMASIN 0.4%, tamoxifen 0.3%.
  • Advanced breast cancer: the most common AEs (AROMASIN vs megestrol acetate) were hot flushes (13% vs 5%), nausea (9% vs 5%), fatigue (8% vs 10%), increased sweating (4% vs 8%), and increased appetite (3% vs 6%).

Dose modification is recommended for patients co-medicated with a potent CYP 3A4 inducer such as rifampin, phenytoin, carbamazepine, Phenobarbital, or St John's wort.

The safety of chronic dosing in patients with moderate or severe hepatic or renal impairment has not been studied.

Please see AROMASIN full Prescribing and Patient Information.

Terms and conditions

By using the AROMASIN Savings Card (the "Card"), you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

  • The Card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare or other federal or state healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico [formerly known as "La Reforma de Salud"])
  • The Card is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs which reimburse you for the entire cost of your prescription drugs
  • With the Card you may pay as low as $4 per prescription of AROMASIN for a maximum savings of $125 per 30-day fill. The offer can be used once per month. Patients can receive a maximum savings of $1,500 per year
  • You must deduct the value received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf
  • The Card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance, or where otherwise prohibited by law
  • This program cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
  • The Card will be accepted only at participating pharmacies
  • This Card is not health insurance. Offer good only in the U.S. and Puerto Rico. The Card is limited to 1 per person during this offering period and is not transferable
  • Pfizer reserves the right to rescind, revoke, or amend the program without notice. No membership fees. Card and Program expire 12/31/2015
  • Pfizer Inc, PO Box 29387, Mission, KS 66201-9618

To learn more about the AROMASIN Savings Card, call 1-866-562-6151.

Please scroll for Important Safety Information and Indication

Important Safety Information

AROMASIN® (exemestane tablets) is contraindicated in patients with known hypersensitivity to the drug or to any of the excipients and in women who are premenopausal, pregnant, or who may become pregnant; the patient should be apprised of the potential hazard to the fetus.

AROMASIN should not be co-administered with estrogen-containing agents as these could interfere with its pharmacologic action.

Reductions in bone mineral density (BMD) over time are seen with AROMASIN use. Clinical fractures were reported in 4.2% of patients receiving AROMASIN and in 3.1% of patients receiving tamoxifen. Therefore, women with osteoporosis or at risk of osteoporosis should have their BMD formally assessed at the commencement of adjuvant treatment with exemestane. Patients treated with exemestane should be carefully monitored and treatment for osteoporosis should be initiated as appropriate.

Adverse Events (AEs): AROMASIN was generally well tolerated and adverse events were usually mild to moderate.

  • Early breast cancer: AEs occurring in ≥10% of patients in any treatment group (AROMASIN vs tamoxifen) were hot flushes (21.2% vs 19.9%), fatigue (16.1% vs 14.7%), arthralgia (14.6% vs 8.6%), headache (13.1% vs 10.8%), insomnia (12.4% vs 8.9%), and increased sweating (11.8% vs 10.4%). Discontinuation rates due to AEs were similar between AROMASIN and tamoxifen. The incidence of cardiac ischemic events (myocardial infarction, angina, and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%. The incidence of cardiac failure was AROMASIN 0.4%, tamoxifen 0.3%.
  • Advanced breast cancer: the most common AEs (AROMASIN vs megestrol acetate) were hot flushes (13% vs 5%), nausea (9% vs 5%), fatigue (8% vs 10%), increased sweating (4% vs 8%), and increased appetite (3% vs 6%).

Dose modification is recommended for patients co-medicated with a potent CYP 3A4 inducer such as rifampin, phenytoin, carbamazepine, Phenobarbital, or St John's wort.

The safety of chronic dosing in patients with moderate or severe hepatic or renal impairment has not been studied.

Please see AROMASIN full Prescribing and Patient Information.

Indication

AROMASIN is indicated for:

  • the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to AROMASIN for completion of a total of 5 consecutive years of adjuvant hormonal therapy.
  • the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.